Benzinga | Apr 15, 2021 12:00PM EDT

GBS, Inc. Receives Approval To Commence Validation Clinical Study For Rapid SARS-CoV-2 Diagnostic Test

GBS, Inc. (NASDAQ:GBS), a life sciences company developing non-invasive, real-time point-of-care (POC) diagnostic tests, and the Wyss Institute for Biologically Inspired Engineering at Harvard University (Wyss Institute) have received approval from the Harvard Longwood campus Institutional Review Board (IRB) to commence a validation study to test clinical samples from a COVID-19 repository.